Yong Il Park et al. successfully developed folate receptor beta (FRβ)-targeted pondus hydrogenii (pH)-sensitive liposomes using docetaxel (DTXL) and doxycycline (DOXY) for the effective treatment of non-small-cell lung cancer [15]. The gene discussed is FOLR2; the disease is non-small cell lung carcinoma.